Leonard Lauder, billionaire heir to cosmetics empire, dies at 92
Leonard Lauder, the eldest son of cosmetics pioneers Estée and Joseph H. Lauder and the former head of cosmetics giant Estée Lauder Companies, seen here in New York on May 5, 2014 has died age 92, according to an announcement by the company. Dennis Van Tine/via CNN Newsource
Leonard Lauder, the eldest son of cosmetics pioneers Estée and Joseph H. Lauder and the former head of cosmetics giant Estée Lauder Companies, died on Saturday, according to an announcement by the company. He was 92.
'Throughout his life, my father worked tirelessly to build and transform the beauty industry, pioneering many of the innovations, trends, and best practices that are foundational to the industry today,' Leonard's son William P. Lauder, who serves as chairman of the company's board of directors, said in the statement.
Born to a Jewish family in New York City, Leonard Lauder as a boy would join his mother on sales calls in salons and helped her pack boxes of powder and cleansing oils. He would later attend and graduate from Columbia University's School of Business after serving as a lieutenant in the US Navy for three years.
He formally joined Estée Lauder at age 25 in 1958, when the company had just a handful of employees and under $1 million in sales.
Estée Lauder Companies would grow into a global empire with a portfolio that includes Clinique, La Mer, The Ordinary, MAC Cosmetics and Bobbi Brown Cosmetics.
Among his many roles included serving as president for 23 years, beginning in 1972, and chief executive from 1982 to 1999. He was named chairman in 1995 and held the role until 2009, according to the company.
In 1995, Lauder took the company public on the New York Stock Exchange at $26 a share. The Estée Lauder Companies Inc. (EL) now has a market capitalization of about $24.3 billion. According to Bloomberg's Billionaire Index, Lauder had a personal net worth of $15.6 billion.
When asked what he would want to be remembered for during a 2020 interview with CBS News, Lauder replied: 'He listened … and he was kind.'
Within 24 hours of meeting Lauder, one could expect intimate, often handwritten, notes from the beauty pioneer. It was a sales technique that resembled the professional style of his mother, who was also known for believing business was about developing and maintaining relationships and making people feel important.
'At the beginning, we never advertised … we gave out samples,' he told David Rubenstein, the co-founder of the Carlyle Group, in 2021. 'We gave out samples that were large enough. If you give a customer a sample of a product and they like it, they come back and buy it again and again and again— that's what builds the business.'
Lauder has been credited with creating 'the lipstick index' during the economic downturn following the attacks on September 11, 2001. He noticed that the purchase of cosmetics, especially lipsticks, tended to be inversely related to the economy because women replaced more expensive purchases with small pick-me-ups. In the fall of 2001, US lipstick sales increased by 11%. And back during the Great Depression, cosmetics sales overall increased by 25%.
Lauder was also a devoted philanthropist and art collector. In 2013, he pledged a 78-piece collection of cubist art to the Metropolitan Museum of Art in New York City — the largest single philanthropic gift in the Met's history, according to Estée Lauder. He also established a research center for modern art at the Met, which supported fellowships, exhibitions and public lectures.
He was also an advocate of cancer research and served as an honorary chairman on the Breast Cancer Research Foundation's board of directors. In 1998, Lauder and his brother, Ronald S. Lauder, founded the Alzheimer's Drug Discovery Foundation, which supports drug research to prevent, treat and cure Alzheimer's.
'His impact will be felt for generations to come thanks to his tireless philanthropy, advocacy, and creativity in tackling some of the world's greatest challenges. The number of lives he touched and positively impacted across all his endeavors is immeasurable,' said Ronald Lauder, 81, who serves as chairman of Clinique Laboratories.
The company's founding family remains the biggest shareholder in the firm, and three members serve on the board of directors.
He is survived by his wife, Judy Glickman Lauder, and his sons William and Gary.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
20 minutes ago
- Globe and Mail
My Top 5 AI Stocks to Buy Before the Second Half
The first half of the year was a turbulent one for stocks in general amid concern President Trump's planned import tariffs would hurt the economy. And this problem weighed most heavily on stocks that depend on growth and investment -- such as those in the field of artificial intelligence (AI). These particular players led indexes higher over the past two years on optimism about spending and the technology's potential, but they lost momentum in March and April. Since, though, the U.S. has made progress on trade talks, and this has lifted market sentiment. Meanwhile, tech companies' earnings reports show no signs of a slowdown in AI spending. Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now. Learn More » This has spurred new gains in AI stocks, and if the U.S. trade situation resolves without excessively high tariffs, these players could continue to advance. With this in mind, here are my top five AI stocks to buy before the second half. 1. Nvidia Nvidia (NASDAQ: NVDA) soared more than 800% over the past two years as investors piled into this stock driving the AI revolution. The company dominates the AI chip market, and these chips are used for the most essential AI tasks. Nvidia hasn't had to wait to benefit from the AI market. The company already has delivered double- or triple-digit growth, with revenue attaining record levels. This momentum is likely to continue as Nvidia is well positioned to power AI across every stage of development, from training through the creation of humanoid robots. I'm confident about this thanks to Nvidia's commitment to innovation -- it's already set out a calendar of chip updates through 2028. This makes it very difficult for rivals to upset its position. Now is a great time to get in on this high-potential player as it's on sale, trading for 33 times forward earnings estimates -- down from more than 50 earlier in the year. 2. Amazon Amazon (NASDAQ: AMZN), which sells some imported goods on its e-commerce site and also works with sellers that import goods, may benefit as trade tensions ease. The company also is winning from AI in two ways: Amazon uses AI tools to streamline operations, resulting in lower costs and greater efficiency. And Amazon, through its cloud unit Amazon Web Services (AWS), sells AI services to customers. AI services already have helped AWS reach a $117 billion annual revenue run rate. All of this could make Amazon a winner in the second half of this year and beyond. On top of this, the company already has demonstrated its earnings strength, growing revenue and profit over time. And its overhaul of its cost structure in recent years should drive even more gains moving forward. Amazon's valuation has fallen from more than 40 times forward earnings estimates earlier this year to 34 times expected earnings, offering investors a bargain entry point right now. 3. SoundHound AI SoundHound AI (NASDAQ: SOUN) shares have dropped more than 50% this year -- not as a result of any negative news, but primarily as investors rotated out of younger growth stocks, seen as risky. This company isn't yet profitable, which is standard at this stage of development, but revenue is soaring -- advancing more than 150% in the latest quarter. This is as customers rush to get in on SoundHound's voice AI technology. The company specializes in this area and has quickly progressed from serving mainly the automobile market to now working with a wide variety of industries, from healthcare to restaurants and financial services. To further emphasize the diversification of its customer base, SoundHound says each single customer represents 10% or less of its revenue. Now is a fantastic time to get in on SoundHound because it's trading for a lower price than earlier this year, and this company still is in the early days of its growth story -- the total addressable market for voice AI is more than $140 billion -- suggesting there's plenty of room for revenue expansion over time. 4. Palantir Technologies Palantir Technologies (NASDAQ: PLTR) has soared over the past year even as valuation has reached mind-boggling levels. The stock trades for more than 200 times forward earnings estimates. But aggressive investors with a long-term view shouldn't necessarily stay away from this high-flyer. Palantir's earnings also have soared, and the ongoing strong demand even prompted the company to lift its revenue, adjusted income from operations, and adjusted free cash flow guidance for the year. What makes this company stand out? Through its software platforms, Palantir helps customers easily harness the power of AI and their own data to streamline their operations, make better and faster decisions, and much more. The company has relied on government customers for years, but in recent times, as the AI boom strengthened and Palantir launched an AI platform, commercial customers knocked on the door. Today, commercial growth is soaring -- and this could be the motor to drive earnings and the stock higher in the quarters to come. This makes Palantir a great growth stock to buy now and hold -- in spite of its lofty valuation. 5. Apple Apple (NASDAQ: AAPL) produces most of its iPhones in China and also manufactures products in India and Vietnam -- and that's why investors have worried about an eventual tax on imports. Even the company's plan to move much of its production of iPhones for the U.S. out of China -- the country most affected by tariffs -- to India won't totally insulate Apple from these extra costs. And Trump recently threatened Apple with a specific tariff of 25% on its imported iPhones. Considering this, why should you buy this tech giant now? The U.S. currently is involved in trade negotiations and potentially even considering the situation of technology players -- it's unlikely the Trump administration will make a decision that would sink Apple or any other U.S. tech giant, so once these times of uncertainty are over, I'm optimistic Apple stock will rebound. Apple has a solid brand moat, or competitive advantage, and that's helped the company steadily grow earnings over time. Today, services offer this powerhouse a new revenue driver that could boost growth for many years down the road considering Apple's base of 2.2 billion active devices -- and this top tech company is in the early stages of AI innovation across its devices. That's why, trading at 27 times forward earnings estimates, Apple is a top stock to buy before the second half. Should you invest $1,000 in Nvidia right now? Before you buy stock in Nvidia, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Nvidia wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $653,702!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $870,207!* Now, it's worth noting Stock Advisor 's total average return is988% — a market-crushing outperformance compared to172%for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of June 9, 2025
Globe and Mail
20 minutes ago
- Globe and Mail
Billionaire Warren Buffett Has a $348 Billion Dilemma -- and His Decision Is Only Getting Tougher
There isn't a money manager on Wall Street who garners more attention from professional and everyday investors than Berkshire Hathaway 's (NYSE: BRK.A)(NYSE: BRK.B) billionaire CEO Warren Buffett. When you deliver an aggregate return for your company's Class A shares (BRK.A) of better than 5,910,000% over six decades (as of the closing bell on June 11), you're going to draw a crowd. But the aptly dubbed "Oracle of Omaha" is also 94 years old and readying to hang up his proverbial work coat. During Berkshire's annual shareholder meeting in early May, Buffett announced his plan to step down as the company's CEO by the end of the year and hand over the reins to predetermined successor Greg Abel. Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now. Continue » Though Warren Buffett's time at the helm is limited, it doesn't change the fact that he's facing a $348 billion dilemma, which is seemingly getting tougher by the day. Warren Buffett has been a net seller of stocks since October 2022 Most investors follow Buffett to get a bead on which stocks he's been buying and selling -- with far more interest in the former than the latter. Riding his coattails has been a profitable investing strategy for decades. While Buffett has, indeed, been purchasing shares of select companies on a quarterly basis, the theme of the last two and a half years is that of Berkshire's chief being a net seller of equities. Berkshire Hathaway's quarterly operating results contain a detailed consolidated cash flow statement that specifically lists "purchases of equity securities" and "sales of equity securities." Some simple arithmetic can allow anyone to decipher whether or not the Oracle of Omaha and his top investment advisors were net buyers or sellers of stocks in the latest quarter. During the March-ended quarter, Warren Buffett sold $1.494 billion more in stocks than was purchased. This marked the 10th consecutive quarter -- a stretch spanning from Oct. 1, 2022 to March 31, 2025 -- where Buffett was a net seller of stocks. On a cumulative basis, Berkshire's head honcho has disposed of $174.4 billion more in stocks than was purchased over this 30-month timeline. All the while, the roughly five dozen businesses Berkshire owns have remained sustainably profitable and continue to generate positive cash from operations. Put this net cash generation together with Buffett's persistent net-selling activity and you get Berkshire Hathaway's cash pile (which includes U.S. Treasuries) ballooning to $347.7 billion. For most companies, an exorbitant cash pile would be a luxury. But for Berkshire Hathaway's lead investor, it's indicative of a dilemma that shows no signs of resolution anytime soon. Buffett is an unwavering value investor who's navigating a historically pricey stock market In an ideal world, the Oracle of Omaha would prefer to put most of his company's capital to work via large investments or acquisitions that would move the needle. Keep in mind that at least $30 billion in combined cash, cash equivalents, and U.S. Treasuries needs to remain on Berkshire's balance sheet to conduct share buybacks, so Buffett won't be dipping below (or generally close to) this level. However, Berkshire's top investor is also unwavering in his desire to get a good deal. Regardless of a company's competitive advantages or rich history, Warren Buffett won't chase pricey stocks higher. He'll patiently sit on his hands and wait for price dislocations to crop up before diving in. Despite Berkshire's cash pile growing to a record $348 billion, Buffett has little-to-no incentive to put this capital to work amid the historic priciness of the stock market. Nearly a quarter of a century ago, in an interview with Fortune magazine, Buffett referred to the market cap-to-GDP ratio as "probably the best single measure of where valuations stand at any given moment." This valuation tool, which aggregates the value of all publicly traded stocks and divides it by U.S. gross domestic product (GDP), has come to be known as the " Buffett Indicator." Warren Buffett Indicator jumps to 200% and is now just 2 percentage points away from the most expensive stock market valuation in history 🚨🚨 -- Barchart (@Barchart) June 10, 2025 When back-tested to 1970, the Buffett Indicator has averaged a reading of approximately 85%, which means the total value of all publicly traded stocks has equated to 85% of U.S. GDP. However, as of the closing bell on June 10, the Buffett Indicator was a few hundredths shy of 202%! It's also within a stone's throw of its all-time high of 205.55%, which was set in mid-February. Another broad-stroke valuation tool that demonstrates what little value can be found on Wall Street at the moment is the S&P 500 's (SNPINDEX: ^GSPC) Shiller price-to-earnings (P/E) Ratio, which may also be referred to as the cyclically adjusted P/E Ratio (CAPE Ratio). The Shiller P/E is based on average inflation-adjusted earnings over the prior 10 years. When back-tested to January 1871, the average Shiller P/E multiple is a touch over 17. As of the closing bell on June 11, the Shiller P/E sported a multiple of more than 37. Although this is down from a peak reading of 38.89 during the current bull market cycle, it marks the third-priciest multiple spanning 154 years. While the Shiller P/E offers no guidance on when stock market corrections will commence, it does have a flawless track record of foreshadowing eventual downside of 20% or more in Wall Street's major stock indexes, including the S&P 500, when surpassing a multiple of 30. Patience is a virtue and a path to profits for the Oracle of Omaha Historically, putting Berkshire Hathaway's capital to work has helped the company grow its sales and/or profits. But until valuation multiples stop going up, it's unlikely that Warren Buffett will be doing much of anything on the investment front, which suggests Berkshire's cash pile is going to continue to expand. However, this isn't necessarily a bad thing -- even if investors are growing weary of the Oracle of Omaha's net-selling activity. To use a baseball analogy, Buffett's outsized investment returns aren't a function of swinging at a lot of pitches. Even though Berkshire Hathaway has more than enough capital that Buffett could, in theory, swing for the fences on a daily basis, his success has been based on waiting for the right pitch to enter his wheelhouse. Regardless of how long it takes, Buffett and his successor Greg Abel have demonstrated a willingness to remain on the sidelines until valuations make sense. For example, Buffett has been purchasing shares of satellite-radio operator Sirius XM Holdings (NASDAQ: SIRI), whose forward P/E ratio of a little over 7 is just shy of its all-time low as a publicly traded company of 31 years. Though Buffett's investment in Sirius XM isn't needle-moving, it's representative of the principles to which Buffett has aligned his investment philosophy. Sirius XM's legal monopoly status ensures its moat, and the company's ultra-low forward P/E presents as a price dislocation amid a historically expensive market. As I've pointed out before, patience paid off handsomely in August 2011 for Berkshire Hathaway and its shareholders when Buffett orchestrated a deal to infuse Bank of America (NYSE: BAC) with $5 billion to shore up its balance sheet. In return, Buffett's company netted $5 billion in BofA preferred stock yielding 6% annually, as well as warrants to purchase up to 700 million shares of Bank of America common stock at $7.14 per share. These warrants were executed in the summer of 2017, leading to an instant (unrealized) profit of $12 billion for Berkshire. Eventually, the lion's share of Berkshire Hathaway's $348 billion in cash will be put to work -- but this won't happen until price dislocations or unique, needle-moving situations present themselves. Should you invest $1,000 in Berkshire Hathaway right now? Before you buy stock in Berkshire Hathaway, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Berkshire Hathaway wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $653,702!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $870,207!* Now, it's worth noting Stock Advisor 's total average return is988% — a market-crushing outperformance compared to172%for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of June 9, 2025
Globe and Mail
an hour ago
- Globe and Mail
Billionaire Stanley Druckenmiller Dumped His Entire Stake in Palantir and Has Piled Into This Suddenly Unstoppable Drug Stock for 3 Straight Quarters
There's nothing more valuable on Wall Street than data, and investors rarely have to dig to find something that's pertinent to the U.S. economy, the stock market, or their specific portfolio holdings. The issue is that between earnings season -- the six-week period where many of America's most-influential public businesses report their operating results each quarter -- and near-daily economic data releases, something important can easily fall through the cracks or slide under the radar of investors. A perfect example being the filing of Form 13Fs with the Securities and Exchange Commission last month. Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now. Continue » No later than 45 calendar days following the end to a quarter, institutional investors with at least $100 million in assets under management are required to file a 13F. This form concisely details which stocks, exchange-traded funds (ETFs), and select options the market's brightest money managers bought and sold in the latest quarter. In other words, it can help investors spot the stocks and trends captivating the attention of the world's best investors. Though Warren Buffett is the most-followed of all asset managers, he's not the only billionaire known for their prescient calls and outsized investment returns. Duquesne Family Office's billionaire chief Stanley Druckenmiller is another money manager who investors wisely pay close attention to. What's particularly noteworthy about Druckenmiller's investment activity of late is his exit from some of Wall Street's most high-flying names in the artificial intelligence (AI) space. Based on Duquesne's first-quarter 13F, Druckenmiller sent his entire stake in Palantir Technologies (NASDAQ: PLTR) packing while continuing to pile into a suddenly unstoppable drug stock for the third consecutive quarter. Duquesne Family Office's billionaire chief bids adieu to Palantir Stanley Druckenmiller initially made waves in the March-ended quarter last year when his fund's 13F showed he added nearly 770,000 shares of Palantir stock. The lure of owning shares of Palantir is the company's irreplaceability. Its two AI and machine learning-driven operating platforms -- Gotham and Foundry -- aren't replicable at scale by any other companies, which leads to highly predictable sales and operating cash flow for Palantir. Gotham lands multiyear contracts with the U.S. government and its immediate allies, while Foundry is a subscription-based service that's generating high margins from enterprise clients looking to better understand their data and streamline their operations. Palantir also brings what's been a sustainably high sales growth rate of 25% to 35% to the table and has been generating recurring profits. But as noted, Duquesne's billionaire chief exited what was left of his fund's Palantir stake at some point during the March-ended quarter -- and there are four possible reasons behind this move. First off, this could be nothing more than simple profit-taking. The 52 positions currently held by Druckenmiller's fund have been there for an average of nine months. This demonstrates he and his team aren't afraid to lock in gains when presented with a sizable move higher in a security. Secondly, there had been rumblings during the first quarter of the Donald Trump administration reducing defense spending in the coming years. President Trump aims to improve the operating efficiency of the federal government, and one theory floated had been the possibility of lowering defense spending. Palantir's Gotham platform plays a critical role in data gathering/analysis, as well as military mission planning and execution. A third possibility that may explain Druckenmiller's exit is the historical precedent of next-big-thing innovations enduring an early innings bubble-bursting event. While Druckenmiller believes in AI as a long-term winner, he's also opined that it's overhyped in the short run. Every next-big-thing trend for more than three decades has worked its way through a bubble-bursting event in its early expansion phase, and AI doesn't look as if it'll be the exception to this unwritten rule. If the AI bubble were to burst, sentiment would weigh heavily on Palantir stock. Fourth, but perhaps most important of all, Palantir Technologies' valuation appears unsustainable. As of closing bell on June 12, Palantir was sporting an astronomical price-to-sales (P/S) ratio of 108! To put this into perspective, prior megacap companies on the leading edge of next-big-thing trends capped out at P/S ratios of between 30 and 43. Even if Palantir stock went sideways for four or five years, it would still be at a historical bubble valuation. Billionaire Druckenmiller has piled into this drug stock for three straight quarters On the other end of the spectrum is a pharmaceutical company that's effected a meaningful turnaround, which billionaire Stanley Druckenmiller has purchased shares of for three consecutive quarters. I'm talking about brand-name and generic-drug developer Teva Pharmaceutical Industries (NYSE: TEVA), whose shares are higher by 142% over the trailing-two-year period (as of the closing bell on June 12). Druckenmiller's fund gobbled up 1,427,950 shares of Teva in the September-ended quarter, added 7,569,450 shares in the December-ended quarter, and picked up another 5,882,350 shares in the March-ended quarter. From the midpoint of 2015 through late 2023, Teva stock lost close to 90% of its value due to a number of headwinds: Its blockbuster multiple sclerosis drug Copaxone lost its sales exclusivity. In hindsight, Teva grossly overpaid for its buyout of generic-drug company Actavis, which ballooned its outstanding debt. Generic-drug pricing power weakened. Teva faced numerous rounds of litigation, including lawsuits regarding its role in the opioid crisis. While these have all been tangible headwinds, current and prior management worked to place these gray clouds in the back seat and have decisively returned Teva to growth. Arguably the biggest advancement for Teva was resolving its opioid litigation. In early 2023, 48 states agreed to a $4.25 billion settlement, which includes up to $1.2 billion worth of a generic version of Narcan (the opioid overdose reversal drug) to be distributed to states by Teva. What's key is that this settlement is spread over 13 years, so it won't be a financial burden to the company. Another major step forward for Teva has been its vastly improved balance sheet. Under turnaround specialist CEO Kare Schultz, the company sold off non-core assets and reduced its operating expenses by billons per year. This prudent focus on spending has continued under current CEO Richard Francis. After tipping the scales with more than $35 billion in net debt following the Actavis deal, Teva now has less than $15 billion in net debt. The other critical action undertaken by Francis has been to shift Teva toward novel-drug development. Though it's still a major player in generic drugs, developing brand-name therapies comes with higher margins and faster growth rates. Tardive dyskinesia drug Austedo looks to push for $2 billion in sales this year, which is up from $963 million in full-year sales in 2022. In other words, Teva has found its Copaxone replacement, and has plenty of other novel therapies ramping up sales and/or in the pipeline. The cherry on top is that Teva Pharmaceutical Industries remains historically cheap despite its stock more than doubling over the trailing-two-year period. Its forward price-to-earnings ratio of 6.5 is well below other major pharmaceutical stocks and not fully indicative of the company's growth potential or ongoing turnaround. Should you invest $1,000 in Palantir Technologies right now? Before you buy stock in Palantir Technologies, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Palantir Technologies wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $653,702!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $870,207!* Now, it's worth noting Stock Advisor 's total average return is988% — a market-crushing outperformance compared to172%for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of June 9, 2025
